Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Choices Clear all
Completed Not applicable Interventional Results available

Mechanisms and Management of Infant Dysphagia

NCT02583360
View directory record Official record
Conditions
Dysphagia, Airway Aspiration, Airway Penetration
Interventions
Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy
Diagnostic Test
Lead sponsor
Sudarshan Jadcherla
Other
Eligibility
38 Weeks to 60 Weeks
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 9, 2026, 7:06 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02117024
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Drug
Lead sponsor
Heat Biologics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Rogers, Arkansas • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

NCT00613080
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
119
States / cities
Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 9, 2026, 7:06 PM EDT
Active, not recruiting Not applicable Interventional

Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial

NCT05656560
View directory record Official record
Conditions
Polypharmacy
Interventions
Clinical decision support (CDS)-Commitment nudge, Clinician education, Clinical decision support (CDS)-Justification nudge
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Not yet recruiting Phase 4 Interventional

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

NCT06660862
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Physician choice Androgen Deprivation (Hormone) Therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
14
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Not yet recruiting Not applicable Interventional

Project SPACE: Testing Daily Text Messages to Reduce Alcohol Use and HIV Risk Behavior

NCT07769580
View directory record Official record
Conditions
HIV, Risk Behavior, Alcohol Abuse
Interventions
CLT- Concrete text messages, CLT- Abstract text messages, Control messages, No messages, GamePlan Online Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Employee Health Through The Worksite Food Environment

NCT02660086
View directory record Official record
Conditions
Weight, Food Choice, Nutrition Intake
Interventions
Personalized nutrition feedback
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 9, 2026, 7:06 PM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

NCT07014462
View directory record Official record
Conditions
AML - Acute Myeloid Leukemia
Interventions
Dexamethasone plus Venetoclax-based Low-Intensity Therapy
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 9, 2026, 7:06 PM EDT
Not yet recruiting Not applicable Interventional

Technology Knowledge Optimization for Type 1 Diabetes in Schools

NCT07482488
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
TeKnO T1D curriculum
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional

Binaural Beats for Postoperative Pain and Anxiety Reduction

NCT07437469
View directory record Official record
Conditions
TKA, THA, Anxiety, Binaural Beats, Music Exposure, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Total Knee Replacement, Total Hip Replacement
Interventions
Binaural Beats Audio Intervention, Music of Choice
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Novel Use of Gamification With Alternative Goal-setting Experiences

NCT03749473
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Choice + Immediate, Choice + Gradual, Assigned + Immediate, Assigned + Gradual, Daily performance feedback, Gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 9, 2026, 7:06 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Metabolic Surgery for Atrial Fibrillation Elimination

NCT07027969
View directory record Official record
Conditions
Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Interventions
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment
Procedure · Drug
Lead sponsor
Ali Aminian
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

NCT07603856
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
55
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional

ACT Intervention for Type 2 Diabetes Management for Rural and Underserved Community

NCT06028503
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Acceptance and Commitment Therapy, Abbott FreeStyle® Libre® 3, Generic Education
Behavioral · Device · Other
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Conroe, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

NCT02384239
View directory record Official record
Conditions
Metastatic Breast Cancer, Hormone Receptor Positive
Interventions
Palbociclib, Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diabetes Prevention Program for Obese Latino Youth

NCT02039141
View directory record Official record
Conditions
Obesity, Insulin Resistance, Diabetes
Interventions
Every Little Step Counts Intervention
Other
Lead sponsor
Arizona State University
Other
Eligibility
14 Years to 16 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NCT07097142
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
211
States / cities
Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions

NCT04601272
View directory record Official record
Conditions
Breast Cancer Screening, Colon Cancer Screening, Prostate Cancer Screening
Interventions
Decision aid
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
35 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 9, 2026, 7:06 PM EDT
Recruiting Not applicable Interventional

Preventing Cognitive Decline by Reducing BP Target Trial

NCT05106036
View directory record Official record
Conditions
Cognitive Decline, Blood Pressure, Hypertension
Interventions
Clinical Support Decision Tool
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 9, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cortisol and Food Insecurity

NCT05191030
View directory record Official record
Conditions
Food Insecurity
Interventions
High-Stress Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 9, 2026, 7:06 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 9, 2026, 7:06 PM EDT